HeartSciences Inc. (HSCS)
NASDAQ: HSCS · Real-Time Price · USD
2.049
+0.049 (2.44%)
Apr 29, 2026, 11:23 AM EDT - Market open
HeartSciences Revenue
HeartSciences had revenue of $8.67K in the twelve months ending January 31, 2026. In the fiscal year ending April 30, 2025, HeartSciences had annual revenue of $4.35K, down -76.61%.
Revenue (ttm)
$8.67K
Revenue Growth
-76.61%
P/S Ratio
735.05
Revenue / Employee
$578
Employees
15
Market Cap
6.53M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Beyond Air | 6.92M |
| Biomerica | 4.33M |
| Tenon Medical | 3.94M |
| Intelligent Bio Solutions | 3.58M |
| Sintx Technologies | 1.02M |
| Co-Diagnostics | 622.49K |
| iTonic Holdings | 523.03K |
| Tivic Health Systems | 482.00K |
HSCS News
- 14 days ago - HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting - GlobeNewsWire
- 5 weeks ago - HeartSciences' MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category - GlobeNewsWire
- 5 weeks ago - HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings - GlobeNewsWire
- 6 weeks ago - HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - University of West England Adopts HeartSciences' MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center - GlobeNewsWire
- 3 months ago - Cibolo Health Designates HeartSciences' MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals - GlobeNewsWire
- 4 months ago - HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device - GlobeNewsWire